Top-line data are expected by the end of 2014...Proceeds would be used to fund clinical trials, R&D for additional alpha-1 antitrypsin (AAT) indications, expanding distribution capabilities for additional territories

Top-line results from that trial are due in mid-2014...MEI Pharma Inc., of San Diego, priced a public offering of about 2 million shares of common stock at $7.50 apiece, a 9.5 percent discount to Thursday's closing price

Cerulean Pharma Inc., of Cambridge, Mass., will present Phase II data for investigational nanopharmaceutical product CRLX101 at the American Association for Cancer Research Annual Meeting...Navidea Biopharmaceuticals Inc., of Dublin, Ohio, disclosed top-line results from the interim analysis of its Phase III trial, NEO3-06, of the imaging agent Lymphoseek for injection in patients with head and neck squamous cell carcinoma

Erytech Pharma SA, of Lyon, France, said it received clearance of its investigational new drug application for a Phase I trial of Eryasp (L-asparagainase-loaded erythrocytes) in patients 40 years and older with newly diagnosed acute lymphoblastic leukemia...Novavax Inc., of Rockville, Md., said top-line data from its Phase II dose-ranging study testing its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age hit its protocol-specified objectives, supporting progression

and Europe, with top-line results due in the second half of 2013...MethylGene Inc., of Montreal, reported top-line results from a trial of MGCD290 in combination with fluconazole for vulvovaginal candidiasis

Antisense Pharma GmbH, of Regensburg, Germany, revised its business objectives related to the advancement of its next-generation TGF-beta inhibitor oligonucleotide program...Top-line data from the RA study are expected midyear

Cerulean Pharma Inc., of Cambridge, Mass., said the first patient was dosed in a Phase II study of CRLX101, a nanopharmaceutical designed to inhibit both topoisomerase 1 and hypoxia-inducible factor-1 alpha, in extensive-stage small-cell lung cancer sensitive to first-line platinum-based chemotherapy...Vanda Pharmaceuticals Inc., of Washington, said top-line data from its Phase IIb/III study, dubbed MAGELLAN, testing tasimelteon as a monotherapy in major depressive disorder (MDD) did not meet the

Top-line data revealed that at the early clinical evaluation point, between 48 hours and 72 hours of treatment initiation, 90.9 percent of subjects were considered to be stable or improving in investigator assessments, meeting the primary endpoint of the study

Alkermes plc, of Dublin, Ireland, reported positive top-line results from a Phase I study of antipsychotic candidate ALKS 3831, which combines a drug molecule ALKS 33 with Zyprexa (olanzapine, Eli Lilly and Co...Cerulean Pharma Inc., of Cambridge, Mass., said it dosed the first patient in a Phase II study of lead candidate CRLX101 in advanced gastric cancer

EyeGate Pharma Inc., of Waltham, Mass., said it enrolled the last patient in a 200-subject pivotal Phase III study of EGP-437 (dexamethasone phosphate ophthalmic solution) in patients with anterior uveitis...Top-line data are expected in the early spring of 2013

Acasti Pharma Inc., of Laval, Quebec, said it achieved significant progress in two ongoing clinical studies with CaPre for lipid management...Top-line data are expected in the latter part of next year

Clavis Pharma ASA, of Oslo, Norway, said it reached the enrollment target for its Phase III CLAVELA study investigating elacytarabine in patients with relapsed or refractory acute myeloid leukemia (AML...Top-line data are expected to be available in Q1 2013

Allon is on track to release top-line data from the trial in the second half of December...Tiltan Pharma Ltd., of Jerusalem, said it enrolled the first U.S

The clinical significance of those analyses is unknown. (See BioWorld Today, March 28, 2012...TransTech Pharma Inc., of High Point, N.C., said recruitment for its recently initiated Phase III trial with TTP054 in Type II diabetics is exceeding expectations with initial top-line results to be available in early 2013

The clinical significance of those analyses is unknown. (See BioWorld Today, March 28, 2012...TransTech Pharma Inc., of High Point, N.C., said recruitment for its recently initiated Phase III trial with TTP054 in Type II diabetics is exceeding expectations with initial top-line results to be available in early 2013

AlphaCore Pharma Inc., of Ann Arbor, Mich., said its Phase I trial met the primary endpoint by demonstrating the safety and tolerability of ACP-501 (recombinant human LCAT...The positive clinical effects of the twice-daily dose of the drug relative to placebo were observed in a variety of standard psoriasis assessment parameters, with the responses accumulating over the 24 weeks...Sophiris Bio Inc., of La Jolla, Calif., released top-line data from the 12-month follow-up of patients receiving PRX302

Top-line data from Genzyme's second Phase III trial, ENCORE, also are expected in early 2013...Top-line data are anticipated in the second quarter of 2013

In April, Biodel reported positive top-line results from a Phase I study of BIOD-123, demonstrating the formulation had more rapid absorption than Humalog (insulin lispro, Eli Lilly and Co.), with comparable injection-site tolerability...The company expects to report top-line safety and efficacy data in the third quarter of 2013...Zealand Pharma A/S, of Copenhagen, Denmark, said it dosed the first patient in a Phase I study of ZP2929, a dual-acting glucagon/GLP-1 peptide agonist, in development for

The company also reported top-line results from its Phase I study of LX7101, an inhibitor of LIM domain kinase 2 (LIMK2), in glaucoma...The companies reported top-line data from AFFIRM last year. (See BioWorld Today, Nov. 4, 2011